Stomach Cancer (Gastric Cancer) Clinical Trials

Ongoing Stomach Cancer (Gastric Cancer) Trials @ NCIS - Patient Recruitment


Protocol Title and Number Patient Selection Criteria Principal Investigator
IP Chemotherapy Study

Feasibility study of intraperitoneal paclitaxel with oxaliplatin and capecitabine in patients with advanced stomach cancer (gastric cancer)

Histologically proven unresectable or recurrent adenocarcinoma of stomach and gastroesophageal junction. Peritoneal metastasis and/or cancer cells on peritoneal cytology. 

 

 

 

 

 

Dr Yong Wei Peng

 

Co-Investigator:

Prof Jimmy So

 

EXPEL Study

Extensive Peritoneal Lavage after Curative Gastrectomy for Stomach Cancer (Gastric Cancer): a Randomized Controlled Trial



Patients who have T3 (subserosal) or T4 (serossal) disease based on CT scan and intra-operative inspection with any N staging and M0 gastric cancer. Patients undergoing gastrectomy with curative intent.



 

 

Prof Jimmy So

 

 

 

REBUILD Study

A Prospective Randomised Study Comparing Billroth II with Roux-en-Y Reconstruction after Radical Distal Subtotal Gastrectomy for Stomach Cancer (Gastric Cancer)

Histopathologically confirmed adenocarcinoma of the distal lesser curve, distal curve, incisura and antrum that are deemed suitable for elective radical subtotal gastrectomy with curative intent.

Prof Jimmy So

 

3G: A Phase II study of genomic-guided ‘standard-of-care’ chemotherapy for in advanced stomach cancer (gastric cancer) patients

Histologically or cytologically documented locally advanced; metastatic or recurrent gastric cancer for which convention therapy of a platinum/fluoropyrimidine combination is indicated; at least one measurable defined by RECIST; Performance status (ECOG) 0-2


 


Dr Yong Wei Peng



A Phase I/IIa study of OTSGC-A24 vaccine in advanced stomach cancer (gastric cancer) Patients must have histologically or cytologically confirmed inoperable or metastatic adenocarcinoma of the stomach or lower third of the oesophagus refractory or intolerable to standard therapy; patients must have measurable or evaluable disease; patients must be HLA-A*2402; patients must have recovered from all reversible treatment toxicity from prior chemotherapy, radiotherapy or surgery. Dr Yong Wei Peng

Feasibility study of intraperitoneal paclitaxel with standard-of-care oxalipatin and capecitabine in patients with advanced stomach cancer (gastric cancer)

 

Histologically proven unresectable or recurrent adenocarcinoma of stomach and gastroesophageal junction; patients without prior systemic treatment. Patients who completed postoperative adjuvant chemotherapy (and radiotherapy) more than 180 days before may be enrolled; peritoneal metastasis and/or cancer cells on peritoneal cytology

 

Dr Yong Wei Peng
Palliative radiotherapy for symptomatic locally advanced stomach cancer (gastric cancer): A Phase II trial

Patients with biopsy confirmed gastric cancer treated with palliative intent, presenting symptom of bleeding, pain and obstruction

Dr Jeremy Tey

*Upcoming
PIPAC - Phase I study of pressurised intraperitoneal aerosol chemotherapy (PIPAC) with oxaliplatin in patients with peritoneal carcinomatosis

Gastric cancer patients with peritoneal metastasis on peritoneal cytology/histology; patients who refuse, unable to tolerate or completed at least first line of systemic chemotherapy; patients who completed chemotherapy/targeted therapy more than 21 days or at least five half-lives (whichever is longer) prior to PIPAC; adequate bone marrow, liver and renal functions; and expected survival of more than three months.
Prof Jimmy So

 

For more information about ongoing Stomach Cancer (Gastric Cancer) Clinical Trials, kindly contact Ms Janelle Phua / Ms Elya at niam_sin_phua@nuhs.edu.sg / surel@nus.edu.sg.